Purpose of this Study
Participants will be randomly assigned to receive either the usual treatment alone or the usual treatment plus the study drug pirtobrutinib. Treatment is given in cycles and includes a combination of cancer medicines called R-CHOP, or a lower dose version called R-mini-CHOP for participants age 75 and older. Researchers will compare how well the treatments work and how safe they are.
Who Can Participate?
Eligibility
Participants may be able to join if they are adults with Richter transformation and are able to carry out most daily activities. They must meet certain heart health requirements if they have a history of heart disease or treatments that can affect the heart. Participants cannot have had major surgery within the past 28 days.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study is testing whether adding the study drug pirtobrutinib to the usual treatment for Richter transformation is safe and works better than the usual treatment alone. Researchers want to learn if the combination can slow the disease from getting worse and help people live longer.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
Yes
Study Details
Full Title
S2504, A Randomized Phase III Study of Pirtobrutinib plus R-CHOP vs. R-CHOP for Participants with Previously Untreated Richter Transformation (pirAMID) NCT #07220187
Principal Investigator
Andrea
Sitlinger
Protocol Number
PRO00120717
NCT ID
NCT07220187
Phase
III
Enrollment Status
Open to Enrollment